keyword
MENU ▼
Read by QxMD icon Read
search

overall survival breast cancer

keyword
https://www.readbyqxmd.com/read/28214052/high-tumor-infiltrating-foxp3-t-cells-predict-poor-survival-in-estrogen-receptor-positive-breast-cancer-a-meta-analysis
#1
F Qian, Y Qingping, W Linquan, H Xiaojin, W Rongshou, R Shanshan, L Wenjun, H Yong, L Enliang
AIMS: Tumor-infiltrating FoxP3(+) T cells and FoxP3(+) tumor cells have been reported in breast cancer (BC), which impaired immunity and promoted tumors progression. However, their prognostic value for survival in patients with breast BC remains controversial. METHODS: A meta-analysis was performed. Original data included the hazard ratios (HR) of overall survival (OS), relapse-free survival and odds ratio (OR) in BC patients. We pooled HR/OR with 95% confidence intervals (CI) to estimate the hazard...
January 30, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28214007/-impact-of-her2%C3%A2-and-brca1-2%C3%A2-status-in-high-dose-chemotherapy-and-autologous-stem-cells-transplantation-in-the-treatment-of-breast-cancer-the-institut-paoli-calmettes-experience
#2
Laurys Boudin, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, Carole Tarpin, Magali Provansal, Gilles Houvenaeghel, Eric Lambaudie, Agnes Tallet, Michel Resbeut, Emmanuelle Charafe-Jauffret, Boris Calmels, Claude Lemarie, Jean-Marie Boher, Jean-Marc Extra, Patrice Viens, Anthony Gonçalves
INTRODUCTION: Studies evaluating chemotherapy high dose chemotherapy with autologous haematopoietic stem cell transplantation (HDC-ACSH) in the treatment of metastatic (MBC), locally advanced (LABC) and inflammatory (IBC) breast cancer have in common lack of biomarker information, in particular the HER2 status. PATIENTS AND METHODS: All consecutive female patients treated for breast cancer with HDC and AHSCT at Institut Paoli Calmettes between 2003 and 2012 were included...
February 14, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28213782/prognosis-of-residual-axillary-disease-after-neoadjuvant-chemotherapy-in-clinically-node-positive-breast-cancer-patients-isolated-tumor-cells-and-micrometastases-carry-a-better-prognosis-than-macrometastases
#3
T J A van Nijnatten, J M Simons, M Moossdorff, L de Munck, M B I Lobbes, C C van der Pol, L B Koppert, E J T Luiten, M L Smidt
PURPOSE: The aim of this study was to compare disease-free survival (DFS) and overall survival (OS) between clinically node-positive breast cancer patients, treated with neoadjuvant chemotherapy (NAC), with axillary pathologic complete response (ypN0), residual axillary isolated tumor cells or micrometastases (ypNitc/mi), and residual axillary macrometastases (ypN1-3). METHODS: All patients diagnosed with clinically node-positive primary invasive breast cancer treated with NAC and subsequent axillary lymph node dissection between 2005 and 2008 were retrospectively analyzed...
February 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28212434/prognostic-and-clinicopathological-value-of-poly-adenosine-diphosphate-ribose-polymerase-expression-in-breast-cancer-a-meta-analysis
#4
Weiqiang Qiao, Linlin Pan, Changgui Kou, Ke Li, Ming Yang
BACKGROUND: Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic value of PARP expression in breast cancer. MATERIALS AND METHODS: Eligible studies were retrieved from the PubMed, Web of Science, Embase, and Cochrane Library databases through July 20, 2016. Studies investigating PARP expression as well as reporting survival data in breast cancer were included...
2017: PloS One
https://www.readbyqxmd.com/read/28211614/opportunities-for-improving-triple-negative-breast-cancer-outcomes-results-of-a-population-based-study
#5
Elisabetta Rapiti, Kim Pinaud, Pierre O Chappuis, Valeria Viassolo, Aurélie Ayme, Isabelle Neyroud-Caspar, Massimo Usel, Christine Bouchardy
Triple-negative breast cancer (TNBC) is associated with a poor prognosis. Surgery, radiotherapy, chemotherapy, and referral for genetic counseling are the standard of care. We assessed TNBC prevalence, management, and outcome using data from the population-based Geneva cancer registry. 2591 women had a first invasive stage I-III breast cancer diagnosed between 2003 and 2011. We compared TNBC to other breast cancers (OBC) by χ(2) -test and logistic regression. Kaplan-Meier survival curves, up to 31-12-2014, were compared using log-rank test...
February 17, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28210563/neoadjuvant-therapy-for-treatment-of-breast-cancer-the-way-forward-or-simply-a-convenient-option-for-patients
#6
COMMENT
Abhishek Chatterjee, John K Erban
The complexity of managing early stage breast cancer is well known. Optimal treatment is increasingly multidisciplinary and in the modern era informed by sophisticated molecular tools to help select and guide therapy. Major phase III trials have determined that the order of systemic therapy relative to surgery does not influence important endpoints such as event free survival and overall survival (OS), but questions remain as to how best to utilize these most essential services. For example, there is still uncertainty regarding the ideal timing, intensity, and duration of proposed therapy...
February 2017: Gland Surgery
https://www.readbyqxmd.com/read/28206964/association-of-15-hydroxyprostaglandin-dehydrogenate-and-poor-prognosis-of-obese-breast-cancer-patients
#7
Ruxing Wu, Tao Liu, Peiwen Yang, Xiyou Liu, Fei Liu, Ya Wang, Huihua Xiong, Shiying Yu, Xiaoyuan Huang, Liang Zhuang
In order to explore the new mechanism that obesity worsens the prognosis of breast cancer, we reanalyzed the data about gene expression of normal, overweight, and obese breast cancer patients to explore potential genes and validate its function by clinical and experimental data. The fold change of 15-hydroxyprostaglandin dehydrogenate (HPGD) gene which displayed declining trend with BMI increase was 0.46 in obese versus normal weight patients. HPGD protein was highest expressed in normal weight group and lowest expressed in obese group...
February 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28206957/young-breast-cancer-patients-who-develop-distant-metastasis-after-surgery-have-better-survival-outcomes-compared-with-elderly-counterparts
#8
Jingjing Wang, Jiayu Wang, Qing Li, Pin Zhang, Peng Yuan, Fei Ma, Yang Luo, Ruigang Cai, Ying Fan, Shanshan Chen, Qiao Li, Binghe Xu
To investigate the recurrence pattern and subsequent survival outcomes in young breast cancer population, 483 young patients (≤ 35) and 739 elderly patients (≥ 65), who received mastectomy or breast-conserving surgery from 2008 to 2012, were included in this study. The young population presented with a higher rate of pathologic tumor stage (P < 0.001), positive pathologic lymph node (P < 0.001), grade III tumors (P < 0.001), and lymphovascular invasion (P < 0.001). With a median follow-up of 56...
February 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28205193/new-therapeutic-strategies-for-triple-negative-breast-cancer
#9
REVIEW
Borbála Székely, Andrea L M Silber, Lajos Pusztai
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options such as immune checkpoint inhibitors and antibody-drug conjugates. Evidence also increasingly supports that platinum drugs and inhibitors of poly (ADP-ribose) polymerase, or PARP, are particularly effective in the treatment of germline BRCA-mutant cancers, including TNBC...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28205044/clinical-tumor-stage-is-the-most-important-predictor-of-pathological-complete-response-rate-after-neoadjuvant-chemotherapy-in-breast-cancer-patients
#10
Briete Goorts, Thiemo J A van Nijnatten, Linda de Munck, Martine Moossdorff, Esther M Heuts, Maaike de Boer, Marc B I Lobbes, Marjolein L Smidt
BACKGROUND: Pathological complete response (pCR) is the ultimate response in breast cancer patients treated with neoadjuvant chemotherapy (NCT). It might be a surrogate outcome for disease-free survival (DFS) and overall survival (OS). We studied the effect of clinical tumor stage (cT-stage) on tumor pCR and the effect of pCR per cT-stage on 5-year OS and DFS. METHODS: Using the Netherlands Cancer Registry, all primary invasive breast cancer patients treated with NCT from 2005 until 2008 were identified...
February 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28205042/screening-relevant-age-threshold-of-70%C3%A2-years-and-older-is-a-stronger-determinant-for-the-choice-of-adjuvant-treatment-in-breast-cancer-patients-than-tumor-biology
#11
E C Inwald, O Ortmann, M Koller, F Zeman, F Hofstädter, M Evert, G Brockhoff, M Klinkhammer-Schalke
PURPOSE: The 70-year threshold determines whether patients are eligible or not for the breast cancer screening program in Germany. It is not known whether this age threshold also influences the choice of adjuvant treatment and ultimate outcome. METHODS: 3463 patients were analyzed from the clinical cancer registry Regensburg (Germany) with primary, non-metastatic invasive breast cancer diagnosed between 2000 and 2012. The distribution of tumor biological subtypes was evaluated in breast cancer patients both in those eligible for screening (ESG, 50-69 years) and those not eligible for screening (NESG, ≥70 years)...
February 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28199747/outcomes-in-patients-with-early-stage-breast-cancer-who-underwent-a-21-gene-expression-assay
#12
Carlos H Barcenas, Akshara Raghavendra, Arup K Sinha, Masood Pasha Syed, Limin Hsu, Modesto G Patangan, Mariana Chavez-MacGregor, Yu Shen, Gabriel H Hortobagyi, Vicente Valero, Sharon H Giordano, Naoto T Ueno, Debu Tripathy
BACKGROUND: Invasive disease-free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), axillary lymph node-negative (LN-) tumors with a 21-gene expression assay recurrence score (RS) of 0 to 10. However, to the authors' knowledge, the outcomes among patients with an RS of 11 to 25 who are treated with endocrine therapy alone are unknown. METHODS: In this retrospective single-institution study, the authors described the characteristics of patients with HR+, HER2-, LN- BC who underwent a 21-gene expression assay...
February 15, 2017: Cancer
https://www.readbyqxmd.com/read/28199006/symptom-incidence-distress-cancer-related-distress-and-adherence-to-chemotherapy-among-african-american-women-with-breast-cancer
#13
Melissa K Yee, Susan M Sereika, Catherine M Bender, Adam M Brufsky, Mary C Connolly, Margaret Q Rosenzweig
BACKGROUND: There is a persistent racial survival disparity between African American (AA) and white women with breast cancer. There is evidence that symptom incidence, associated distress, and overall cancer-related distress may be unexplored, important contributing factors. The purpose of the current study was to: 1) describe and compare the number of chemotherapy-related symptoms and associated distress among AA women with breast cancer over the course of chemotherapy at 3 time points (at baseline before initiating chemotherapy, midpoint, and at the completion of chemotherapy); and 2) to describe the relationship between the number of chemotherapy-related symptoms and overall cancer distress compared with the ability to receive at least 85% of the prescribed chemotherapy within the prescribed timeframe...
February 15, 2017: Cancer
https://www.readbyqxmd.com/read/28198505/migration-and-invasion-enhancer-1-mien1-is-overexpressed-in-breast-cancer-and-is-a-potential-new-therapeutic-molecular-target
#14
H-B Zhao, X-F Zhang, H-B Wang, M-Z Zhang
Migration and invasion enhancer 1 (MIEN1) is a membrane-anchored protein that is highly expressed in various types of cancer, and is correlated with the PI3K/AKT pathway. The aim of this study was to investigate the expression of MIEN1 and its clinical pathological significance in breast cancer. We used immunohistochemical staining to examine the expression of MIEN1 in 40 samples of human breast cancer tissue and 10 samples taken from regions adjacent to normal breast tissue. The rate of detection of MIEN1 protein was 67...
February 8, 2017: Genetics and Molecular Research: GMR
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#15
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28195084/calretinin-expression-as-a-reliable-prognostic-marker-in-different-molecular-subtypes-of-breast-carcinoma
#16
Mayada Saad Farrag, Amro Awad El-Karef, Maha Mohammed Amin, Nagwa Mokhtar Helal, Omar Farouk Ali, Nesrine Saad Farrag
BACKGROUND: Calretinin (CR), a known mesothelial marker, is expressed in both epithelial and mesenchymal malignancies including breast cancer. AIMS: We aimed to measure the frequency of CR expression in correlation with other clinicopathological parameters of different molecular subtypes of invasive breast carcinoma and to study its prognostic implications in this common cancer. STUDY DESIGN: Tissue microarrays were constructed from 225 tissue samples of breast carcinoma cases...
January 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28194538/the-influences-of-peritumoral-lymphatic-invasion-and-vascular-invasion-on-the-survival-and-recurrence-according-to-the-molecular-subtypes-of-breast-cancer
#17
Ki-Tae Hwang, Young A Kim, Jongjin Kim, A Jung Chu, Ji Hyun Chang, So Won Oh, Kyu Ri Hwang, Young Jun Chai
PURPOSE: We aimed to compare the influences of lymphatic invasion (LI) and vascular invasion (VI) on survival and recurrence according to the molecular subtypes of breast cancer. METHODS: We retrospectively analyzed data on 820 breast cancer patients and assessed overall survival (OS) and disease-free survival (DFS) according to LI and VI using the Kaplan-Meier estimator and the Cox proportional hazards model. RESULTS: Both positive LI and positive VI showed inferior OS and DFS compared with negative LI and negative VI (all p < 0...
February 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28194325/serum-yb-1-y-box-binding-protein-1-as-a-biomarker-of-bone-disease-progression-in-patients-with-breast-cancer-and-bone-metastases
#18
A R Ferreira, M Bettencourt, I Alho, A L Costa, A R Sousa, A Mansinho, C Abreu, C Pulido, D Macedo, I Vendrell, T R Pacheco, L Costa, S Casimiro
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock protein that has been implicated in all hallmarks of cancer. Elevated YB-1 protein level was associated with poor prognosis in several types of cancers, including breast cancer (BC), where it is a marker of decreased overall survival (OS) and distant metastasis-free survival across all subtypes. YB-1 is also secreted by different cell types and may act as an extracellular mitogen; however the pathological implications of the secreted form of YB-1 (sYB-1) are unknown...
March 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28193572/systematic-review-of-early-and-long-term-outcome-of-liver-resection-for-metastatic-breast-cancer-is-there-a-survival-benefit
#19
REVIEW
Tae Gon Yoo, Isaac Cranshaw, Reuben Broom, Sanjay Pandanaboyana, Adam Bartlett
BACKGROUND: Isolated liver metastases occur rarely in patients with metastatic breast cancer. The success of liver resection (LR) for other metastatic disease has led centres to explore the option of LR for patients with isolated breast cancer liver metastases (BCLM). A number of small series have been published in the literature, however the evidence is conflicting. This study aimed to systematically review the literature to determine the perioperative outcome and survival of patients undergoing LR for BCLM...
February 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28193571/outcomes-and-utilization-of-postmastectomy-radiotherapy-for-t3n0-breast-cancers
#20
Samual R Francis, Jonathan Frandsen, Kristine E Kokeny, David K Gaffney, Matthew M Poppe
BACKGROUND: The role of postmastectomy radiotherapy (PMRT) for women with pT3N0M0 breast cancer is controversial. We sought to determine the benefit of PMRT in this cohort using the National Cancer Database (NCDB). METHODS: We analyzed women with pT3N0M0 breast cancer who received mastectomy with or without PMRT between 2004 and 2012. We excluded men, women ≤18 years, neoadjuvant or unknown radiation or chemotherapy status, unknown estrogen or progesterone receptor status, unknown surgical margin status, histology other than invasive ductal or lobular carcinoma, and if death occurred <3 months after diagnosis...
February 9, 2017: Breast: Official Journal of the European Society of Mastology
keyword
keyword
107111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"